These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28994343)

  • 1. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Cencini E; Puccini B; Rigacci L; Fabbri A; Kovalchuk S; Mannelli L; Benelli G; Carfagno T; Simontacchi G; Bocchia M; Bosi A
    Leuk Lymphoma; 2018 Jun; 59(6):1420-1426. PubMed ID: 28994343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Leuk Lymphoma; 2015; 56(8):2350-6. PubMed ID: 25426666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
    Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
    Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
    PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
    Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
    Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
    Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
    König L; Herfarth K; Hörner-Rieber J; Dietrich S; Wiegel T; Debus J; Viardot A
    Strahlenther Onkol; 2020 Aug; 196(8):705-714. PubMed ID: 32377821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance rituximab in Veterans with follicular lymphoma.
    Halwani AS; Rasmussen KM; Patil V; Morreall D; Li C; Yong C; Burningham Z; Dawson K; Masaquel A; Henderson K; DeLong-Sieg E; Sauer BC
    Cancer Med; 2020 Oct; 9(20):7537-7547. PubMed ID: 32860335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment.
    Sancho JM; García O; Mercadal S; Pomares H; Fernández-Alvarez R; González-Barca E; Tapia G; González-García E; Moreno M; Domingo-Domènech E; Sorigué M; Navarro JT; Motlló C; Fernández-de-Sevilla A; Feliu E; Ribera JM
    Leuk Res; 2015 Aug; 39(8):853-8. PubMed ID: 26122511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
    Bari A; Marcheselli R; Marcheselli L; Alvarez I; Pozzi S; Ferri P; Lazzaro A; Fragasso A; Neri S; Baldini L; Carella AM; Angrilli F; Guariglia R; Buda G; Stelitano C; Sacchi S;
    Acta Haematol; 2017; 137(1):7-14. PubMed ID: 27820922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
    MacManus M; Fisher R; Roos D; O'Brien P; Macann A; Davis S; Tsang R; Christie D; McClure B; Joseph D; Jayamohan J; Seymour JF
    J Clin Oncol; 2018 Oct; 36(29):2918-2925. PubMed ID: 29975623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
    Nagai H; Shimomura T; Takeuchi M; Hanada S; Komeno T; Sunami K; Hidaka M; Yano T; Kitano K; Yoshida I; Inoue N; Saito A; Horibe K; Motitani S; Ichihara S; Watanabe T; Sawamura M
    Leuk Lymphoma; 2017 Dec; 58(12):2845-2851. PubMed ID: 28509595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
    Moccia AA; Zucca E; Ghielmini M
    Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.